Eyelid Thermal Pulsation for the Treatment of Dry Eye Syndrome
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage of eyelid thermal pulsation therapies (vectored or automated heat + pulsation devices and related imaging) for treatment of meibomian gland dysfunction/dry eye syndrome for BCBSRI members, including Medicare Advantage and commercial products.
No material clinical or coverage changes in this revision.
Coverage determinations
Coverage stance by product
Coverage determinations by product:
chunk 4
chunk 5
Not covered services
Specific services identified as not covered / not medically necessary:
Benefits for eyelid thermal pulsation therapies may vary between employer groups and specific member contracts. For member-specific coverage determinations, providers should refer to the Evidence of Coverage or the Subscriber Agreement, which govern applicable benefits and supersede this policy.
For commercial products, eyelid thermal pulsation therapy to treat dry eye syndrome is considered not medically necessary because the evidence is insufficient to determine the effects of the technology on health outcomes. This determination applies to the procedures and services listed in the policy (see coding section).
Procedure and billing codes
| 0207T | Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral |
| 0330T | Tear film imaging, unilateral or bilateral, with interpretation and report: (eg, LipiView Ocular Surface Interferometer) |
| 0507T | Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report |
| 0563T | Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral |
What providers should do
Prior Authorization
Prior authorization is not applicable for this policy.
Step Therapy
No step therapy requirements specified for eyelid thermal pulsation therapy in this policy.
Coverage / Denial Risk
Eyelid thermal pulsation therapy to treat dry eye syndrome is not covered for Medicare Advantage plans and is considered not medically necessary for commercial products due to insufficient evidence of clinical benefit.
Verify Member Benefits
Providers should verify member-specific benefits and eligibility prior to providing services; benefits may vary between groups/contracts and the Evidence of Coverage or Subscriber Agreement governs applicable coverage determinations.
Clinical background
Meibomian gland dysfunction (MGD) is a disorder of the meibomian glands and is recognized as the major cause of evaporative dry eye syndrome. Symptoms of MGD-related dry eye can include ocular irritation, fluctuating vision, and tear film instability.
Thermal pulsation is a treatment approach that applies controlled heat to the palpebral surfaces of the upper and lower eyelids overlying the meibomian glands while simultaneously delivering graded pulsatile pressure to express gland contents. Device-based thermal pulsation aims to relieve gland obstruction and improve lipid layer quality, and it is offered as an alternative to standard treatments such as warm compresses, eyelid hygiene, manual gland expression, and topical medications. The policy evaluates these technologies and finds current evidence insufficient to demonstrate improved health outcomes for the indicated use.
Key terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.